Robotic and Laparoscopic Hysterectomy Show Equivalent Oncologic OutcomesRobotic surgery shows similar survival outcomes for endometrial cancer patients

This meta-analysis, encompassing 91,151 patients with endometrial cancer undergoing hysterectomy, provides a comprehensive comparison of robotic-assisted surgery versus conventional laparoscopy. The primary focus was on oncologic outcomes, including recurrence, progression-free survival (PFS), and overall survival (OS). The analysis revealed that both surgical approaches yield equivalent results across these critical endpoints, indicating that the choice of platform does not compromise cancer control. This equivalence is a key finding, as it reassures clinicians that both minimally invasive options are viable for treating endometrial cancer.

Secondary outcomes further characterized the perioperative profiles of each technique. Lymph node yield, a surrogate for surgical staging adequacy, was similar between the robotic and laparoscopic groups, suggesting comparable oncologic thoroughness. Estimated blood loss (EBL) was reduced in the robotic group, a potential advantage in terms of hemodynamic stability and transfusion requirements. Additionally, the rate of conversion to open surgery was lower with robotic assistance, which may reflect enhanced dexterity and visualization, particularly in complex cases.

However, intraoperative complications were slightly more frequent in the robotic group. While the absolute difference was not reported, this finding warrants attention. Possible explanations include the learning curve associated with robotic platforms, patient selection, or the complexity of cases chosen for robotic surgery. Despite this, the overall complication rates appear low, and the clinical significance of this slight increase remains uncertain.

Operative time was also assessed, though the direction of effect was not specified in the main results. Typically, robotic surgery may have longer operative times initially, but this can decrease with experience. The meta-analysis did not report a significant difference, suggesting that operative time may be comparable between the two approaches in experienced hands.

The study's large sample size enhances the statistical power and generalizability of the findings. However, limitations were not reported, which is a gap. Potential limitations could include heterogeneity among included studies, variations in surgeon expertise, and differences in patient characteristics. These factors could influence the outcomes and should be considered when interpreting the results.

From a clinical perspective, these findings support the use of either robotic or laparoscopic hysterectomy for endometrial cancer, with the choice guided by institutional resources, surgeon expertise, and patient-specific factors. The equivalence in oncologic outcomes means that decisions can be based on other considerations, such as cost, availability, and patient preferences. The perioperative advantages of robotic surgery, such as reduced blood loss and fewer conversions, may be particularly beneficial in certain patient populations, such as those with obesity or complex anatomy.

In conclusion, this meta-analysis provides robust evidence that robotic-assisted and conventional laparoscopic hysterectomy offer comparable oncologic outcomes for endometrial cancer. The modest differences in perioperative outcomes are unlikely to alter clinical practice significantly. Instead, the focus should remain on ensuring that patients receive timely, high-quality minimally invasive surgery, regardless of the specific platform used. Future research should aim to identify which patients might benefit most from each approach and to address the slight increase in intraoperative complications associated with robotic surgery.